TY  - JOUR
T1  - IMproving access to fda reviews and documents
AU  - Tuttle DA, Sasich LD, Sukkari SR
Y1  - 2009/11/25
N1  - 10.1001/jama.2009.1726
JO  - JAMA
SP  - 2204
EP  - 2205
VL  - 302
IS  - 20
N2  - 
To the Editor: The Commentary by Dr O’Connor1 highlighted the importance of using publicly available US Food and Drug Administration (FDA) review documents in conducting independent assessments of the therapeutic value of new drugs. Many trials submitted to the FDA were recently found to be unpublished 5 years after new drug approvals.2 Accordingly, the information that is easily available in the published medical literature is incomplete and potentially biased.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2009.1726
UR  - http://dx.doi.org/10.1001/jama.2009.1726
ER  -